107 related articles for article (PubMed ID: 8152795)
1. Overlapping domains on the p53 protein regulate its transcriptional activation and repression functions.
Subler MA; Martin DW; Deb S
Oncogene; 1994 May; 9(5):1351-9. PubMed ID: 8152795
[TBL] [Abstract][Full Text] [Related]
2. Hetero-oligomerization does not compromise 'gain of function' of tumor-derived p53 mutants.
Deb D; Scian M; Roth KE; Li W; Keiger J; Chakraborti AS; Deb SP; Deb S
Oncogene; 2002 Jan; 21(2):176-89. PubMed ID: 11803461
[TBL] [Abstract][Full Text] [Related]
3. The basic carboxy-terminal domain of human p53 is dispensable for both transcriptional regulation and inhibition of tumor cell growth.
Pellegata NS; Cajot JF; Stanbridge EJ
Oncogene; 1995 Jul; 11(2):337-49. PubMed ID: 7624148
[TBL] [Abstract][Full Text] [Related]
4. 'Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain.
Lányi A; Deb D; Seymour RC; Ludes-Meyers JH; Subler MA; Deb S
Oncogene; 1998 Jun; 16(24):3169-76. PubMed ID: 9671396
[TBL] [Abstract][Full Text] [Related]
5. Dominance of wild-type p53-mediated transcriptional activation in breast epithelial cells.
Davis P; Bazar K; Huper G; Lozano G; Marks J; Iglehart JD
Oncogene; 1996 Sep; 13(6):1315-22. PubMed ID: 8808706
[TBL] [Abstract][Full Text] [Related]
6. Distinct regions of p53 have a differential role in transcriptional activation and repression functions.
Sang BC; Chen JY; Minna J; Barbosa MS
Oncogene; 1994 Mar; 9(3):853-9. PubMed ID: 8108128
[TBL] [Abstract][Full Text] [Related]
7. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
Inga A; Resnick MA
Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
[TBL] [Abstract][Full Text] [Related]
8. Analysis of p53 transactivation through high-affinity binding sites.
Chumakov AM; Miller CW; Chen DL; Koeffler HP
Oncogene; 1993 Nov; 8(11):3005-11. PubMed ID: 8414502
[TBL] [Abstract][Full Text] [Related]
9. Mutant p53 proteins have diverse intracellular abilities to oligomerize and activate transcription.
Miller CW; Chumakov A; Said J; Chen DL; Aslo A; Koeffler HP
Oncogene; 1993 Jul; 8(7):1815-24. PubMed ID: 8510927
[TBL] [Abstract][Full Text] [Related]
10. Interaction of human polyomavirus BK with the tumor-suppressor protein p53.
Shivakumar CV; Das GC
Oncogene; 1996 Jul; 13(2):323-32. PubMed ID: 8710371
[TBL] [Abstract][Full Text] [Related]
11. p53 transactivation domain mutant Q22, S23 is impaired for repression of promoters and mediation of apoptosis.
Roemer K; Mueller-Lantzsch N
Oncogene; 1996 May; 12(10):2069-79. PubMed ID: 8668332
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional repression by the C-terminal domain of p53.
Shaulian E; Haviv I; Shaul Y; Oren M
Oncogene; 1995 Feb; 10(4):671-80. PubMed ID: 7862444
[TBL] [Abstract][Full Text] [Related]
13. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.
Campomenosi P; Monti P; Aprile A; Abbondandolo A; Frebourg T; Gold B; Crook T; Inga A; Resnick MA; Iggo R; Fronza G
Oncogene; 2001 Jun; 20(27):3573-9. PubMed ID: 11429705
[TBL] [Abstract][Full Text] [Related]
14. Cell-specific modulation of the papovavirus promoters by tumor-suppressor protein p53 in the absence of large T-antigen.
Das GC; Shivakumar CV; Todd SD
Oncogene; 1995 Feb; 10(3):449-55. PubMed ID: 7845669
[TBL] [Abstract][Full Text] [Related]
15. The E6 protein of human papillomavirus type 16 functions as a transcriptional repressor in a mechanism independent of the tumor suppressor protein, p53.
Etscheid BG; Foster SA; Galloway DA
Virology; 1994 Dec; 205(2):583-5. PubMed ID: 7975261
[TBL] [Abstract][Full Text] [Related]
16. Tumour associated mutants of p53 can inhibit transcriptional activity of p53 without heterooligomerization.
Jõers A; Kristjuhan A; Kadaja L; Maimets T
Oncogene; 1998 Nov; 17(18):2351-8. PubMed ID: 9811466
[TBL] [Abstract][Full Text] [Related]
17. p53-dependent repression of the human MCL-1 gene encoding an anti-apoptotic member of the BCL-2 family: the role of Sp1 and of basic transcription factor binding sites in the MCL-1 promoter.
Pietrzak M; Puzianowska-Kuznicka M
Biol Chem; 2008 Apr; 389(4):383-93. PubMed ID: 18208354
[TBL] [Abstract][Full Text] [Related]
18. Physical and functional interactions between members of the tumour suppressor p53 and the Sp families of transcription factors: importance for the regulation of genes involved in cell-cycle arrest and apoptosis.
Koutsodontis G; Vasilaki E; Chou WC; Papakosta P; Kardassis D
Biochem J; 2005 Jul; 389(Pt 2):443-55. PubMed ID: 15790310
[TBL] [Abstract][Full Text] [Related]
19. [Protein p53 inhibits the activity of the enhancer of the immediate-early genes of murine cytomegalovirus].
Lembo D; Angeretti A; Cavallo R; Gariglio M; Gribaudo G; Landolfo S
G Batteriol Virol Immunol; 1994; 86(1-12):43-54. PubMed ID: 8706975
[TBL] [Abstract][Full Text] [Related]
20. Adenoviral expression of p53 represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcription.
Kanaya T; Kyo S; Hamada K; Takakura M; Kitagawa Y; Harada H; Inoue M
Clin Cancer Res; 2000 Apr; 6(4):1239-47. PubMed ID: 10778946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
